Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by SizzlinSteakson Mar 20, 2018 3:55pm

136 Views

Post# 27748893

RE:ATE loaded with Venture penny fliipers

Comparing NXT to ATE??? ....that in itself is a JOKE

cohiba wrote: Who have an attention span of about 48 hours. This goes to the .40's once they get bored, Check NXT for proof. ATE a very long term play. FDA approval could take years and tens of millions. This is the sordid TSX Venture exchange. Never forget that.

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025